Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06835816
Recruiting Not applicable

Amino Acid Supplementation in Continuous Renal Replacement Therapy

NCT06835816 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska University Hospital
Phase
Not applicable
Started
2025-02-03
Last updated
2025-02-19

Condition(s) studied

Acute Kidney Injury

Investigational drug(s) / intervention(s)

Amino acid supplementation (Glavamin, Fresenius Kabi)

Amino acid supplementation (Glavamin, Fresenius Kabi): Mixture of amino acids (67 g / 500 ml) given intravenously

Study summary

ICU patients treated with continuous renal replacement therapy is recruited prior to start of treatment.

Blood samples are drawn and then dialysis start without amino acid supplementation. After a few hours samples are drawn from blood and dialysate. Then patients are given amino acid supplementation (33.5g/24hrs) for 20-24 hours. New samples are drawn and amino acid supplementation is increased to 67g/24hrs and new samples are drawn after additional 24 hours. Then CRRT will continue with the full amino acid supplementation (standars of care).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Dialysis where amino acid supplementation is planned by treating physician Exclusion Criteria: * Liver failure * Muscle disease * Neurodegenerative disease

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Karolinska University Hospital Stockholm Sweden Recruiting

More Karolinska University Hospital trials in Sweden

Ablation of Fibrotic Areas in Patients With Persistent Atrial Fibrillation. Active, not recruiting
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases Recruiting
Timing of Renal Replacement Therapy in the Critically Ill Patients Recruiting
TENS for Relief of Postoperative Pain in Orthopedic Patients Active, not recruiting
Follow-up of Cell Changes in the Cervix Active, not recruiting

Other trials for the same condition

Timing of Renal Replacement Therapy in the Critically Ill Patients Recruiting
Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery Recruiting
Inflammatory Mediators of Acute Kidney Injury in Intensive Care Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06835816 on ClinicalTrials.gov ↗ ← All trials in Sweden